Focus Areas in the Genomic Medicine Cycle
Major leadership positions
Director, Psychiatric and Neurodevelopmental Genetics Unit, MGH Center for Genomic Medicine
Director, Center for Precision Psychiatry, MGH
Associate Chief for Research Department of Psychiatry, MGH
Director, Omics Unit, MGH Division of Clinical Research
Director, Mass General Brigham Training Program in Precision and Genomic Medicine
President, International Society of Psychiatric Genetics
MGH Unit(s)
Psychiatric and Neurodevelopmental Genetics Unit, MGH Center for Genomic Medicine
Center for Precision Psychiatry, MGH Department of Psychiatry
Overview
- Genetic Basis of Psychiatric Disorders
- Integrating Genomic & Neuroscience
- Precision Medicine & computational health Research
The focus of Dr. Smoller’s research interests has been:
- Understanding the genetic and environmental determinants of psychiatric disorders across the lifespan.
- Integrating genomics and neuroscience to unravel how genes affect brain structure and function.
- Using “big data”, including electronic health records and genomics, to advance precision medicine.
Priority Projects
-
PsycheMERGE: Leveraging electronic health records and genomics for mental health research. This study aims to leverage resources from the eMERGE Network to phenotypically and genomically validate and harmonize psychiatric phenotypes across multiple disorders, build clinically useful risk surveillance models for mood disorders, and examine whether risk profiles are associated with clinically-relevant health outcomes.
R01 MH118233 (Smoller/Davis) | 02/15/19-11/30/22 -
Understanding the Connections among Genes, Environment, Family Processes and Mental Health. The goal of this project is to examine genetic and environmental predictors of risk and resilience for psychiatric disorders and family outcomes and examine the transethnic effects of previously established risk factors in a long-term community and family panel study in Nepal.
R01 MH110872 (Axinn/Smoller) | 09/01/17-06/30/22
-
Improved Multifactorial Prediction of Suicidal Behavior Through Integration of Multiple Datasets. The goal of this project is to improve existing EHR-based suicide risk prediction models by integrating additional sources of information including sociodemographic data, to create multifactorial predictive models of suicidal behavior risk.
R01 MH117599 (Smoller/Reis) | 08/13/18-05/31/23 -
eMERGE Phase IV Clinical Center at Partners HealthCare. The team will work on implementation of phenotype algorithms for eMERGE IV, develop new algorithms using EHR data extraction, natural language processing, and machine learning, implement cross-network phenotypes, and provide lineage between genotypes and phenotypes. The team will perform data extraction from the EHR into the Biobank Portal and from there into the OMOP common data model and transfer of data to the Coordinating Center, as well as AnVIL.
2U01 HG008685 (Karlson, E.W.) | 07/01/20-04/30/25
Lab Members
| Name: | Email: | Role: |
|---|---|---|
| Kate Bentley, PhD | KBENTLEY [@] mgh.harvard.edu | Assistant Professor of Psychology in the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School |
| Karmel Choi, PhD | KWCHOI [@] mgh.harvard.edu | Assistant Professor of Psychology in the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School |
| Tian Ge, PhD | TGE1 [@] PARTNERS.ORG | Assistant Professor of Psychiatry, Massachusetts General Hospital and Harvard Medical School |
| Christy Denckla | cdenckla [@] hsph.harvard.edu | Assistant Professor of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health |
Lab/Contact Telephone
617-724-0835
Fax
617-726-0830
The Center for Genomic Medicine (CGM) comprises one of the largest and most vibrant hubs of genomic medicine research in the world. The CGM includes 46 faculty collaborating to define the ‘genomic medicine cycle’ – which envisages a genomics community seeking to advance research from basic genomics research to ultimately using genome information for diagnostics and targeted therapeutics. All of our investigators are faculty at Harvard Medical School, and many members of our community are also investigators at the Broad Institute of Harvard and MIT.
